Literature DB >> 16998757

Rare indications of IVIG therapy in neurological diseases based on case reports and small studies.

Hayrettin Tumani1.   

Abstract

IVIG treatment has been tried in several neurological diseases with presumed immunopathogenesis. Many of the rare neurological diseases seem to benefit from IVIG treatment; however, negative results have been rarely published. Despite the majority of positive results, a general use of IVIG cannot be recommended for these diseases. Beside the lack of controlled studies and the small numbers of reported cases, a publication bias has to be considered since negative study results are usually not reported. Therefore, at this stage treatment with IVIG should be used in conjunction with controlled therapy trials.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16998757     DOI: 10.1007/s00415-006-5011-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  20 in total

1.  High-dose intravenous immune globulin for stiff-person syndrome.

Authors:  M C Dalakas; M Fujii; M Li; B Lutfi; J Kyhos; B McElroy
Journal:  N Engl J Med       Date:  2001-12-27       Impact factor: 91.245

2.  Treatment of idiopathic lumbosacral plexopathy with intravenous immunoglobulin.

Authors:  W J Triggs; M S Young; T Eskin; E Valenstein
Journal:  Muscle Nerve       Date:  1997-02       Impact factor: 3.217

3.  Treatment of acute disseminated encephalomyelitis with intravenous immunoglobulin.

Authors:  D J Sahlas; S P Miller; M Guerin; M Veilleux; G Francis
Journal:  Neurology       Date:  2000-03-28       Impact factor: 9.910

4.  Immunoglobulins are effective in pontine myelinolysis.

Authors:  J Finsterer; E Engelmayer; E Trnka; M Stiskal
Journal:  Clin Neuropharmacol       Date:  2000 Mar-Apr       Impact factor: 1.592

5.  The prognosis and long-term course of viral encephalitis.

Authors:  P Berlit
Journal:  J Neuroimmunol       Date:  1988-12       Impact factor: 3.478

6.  Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis.

Authors:  M Nakagawa; K Nakahara; Y Maruyama; M Kawabata; I Higuchi; H Kubota; S Izumo; K Arimura; M Osame
Journal:  J Neurovirol       Date:  1996-10       Impact factor: 2.643

7.  High dose immunoglobulin IV treatment in adrenoleukodystrophy.

Authors:  M Cappa; E Bertini; P del Balzo; P Cambiaso; A Di Biase; S Salvati
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 8.  Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome.

Authors:  Masaaki Odaka; Nobuhiro Yuki; Mitsunori Yamada; Michiaki Koga; Toshihiko Takemi; Koichi Hirata; Satoshi Kuwabara
Journal:  Brain       Date:  2003-07-07       Impact factor: 13.501

9.  Intravenous immunoglobulins in infectious diseases: where do we stand?

Authors:  L Mouthon; O Lortholary
Journal:  Clin Microbiol Infect       Date:  2003-05       Impact factor: 8.067

10.  High-dose intravenous immunoglobulin therapy in chronic progressive lumbosacral plexopathy.

Authors:  A Verma; W G Bradley
Journal:  Neurology       Date:  1994-02       Impact factor: 9.910

View more
  1 in total

1.  Intravenous immune globulin usage for neurological and neuromuscular disorders: an academic centre, 4 years experience.

Authors:  Lisa Sarti; Tiziana Falai; Francesco Pinto; Enrico Tendi; Sabrina Matà
Journal:  Neurol Sci       Date:  2009-03-04       Impact factor: 3.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.